Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice

Journal of Physiology

Volumn 558, Issue 2, 2004, Pages 647-657

  Pacher, Pál ^a   Bátkai, Sándor ^a   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; VANILLOID RECEPTOR 1; CAPSAICIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR REFLEX; CATHETER; CONTROLLED STUDY; DIASTOLE; DRUG BLOOD LEVEL; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART PRELOAD; HEART RATE; HEMODYNAMICS; HYPOTENSION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRESSOR RESPONSE; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; SYSTOLE; VASCULAR RESISTANCE; WILD TYPE; ANALYTICAL EQUIPMENT; BEZOLD JARISCH REFLEX; CALIBRATION; COMPARATIVE STUDY; HEART HEMODYNAMICS; MEAN ARTERIAL PRESSURE; MILLAR PRESSURE VOLUME CONDUCTANCE CATHETER SYSTEM; MOLECULAR DYNAMICS; SYMPATHETIC REFLEX;

ANIMALS; ARACHIDONIC ACIDS; BLOOD PRESSURE; CAPSAICIN; ENDOCANNABINOIDS; HYPOTENSION; ION CHANNELS; MALE; MICE; MICE, KNOCKOUT; NEURONS, AFFERENT; POLYUNSATURATED ALKAMIDES; REFLEX; SYMPATHETIC NERVOUS SYSTEM; TRPV CATION CHANNELS; VENTRICULAR PRESSURE;

EID: 4344627156     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2004.064824     Document Type: Article

References (43)

1. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbascheck R, Garcia N Jr, Sanyal AJ & Kunos G (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7, 827-832.
2. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G & Wagner JA (2003). Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41, 657-664.
3. Di Marzo V, Bisogno T, Melck D, Ross R, Brockie H, Stevenson L, Pertwee R & De Petrocellis L (1998). Interactions between synthetic vanilloids and the endogenous cannabinoids system. FEBS Lett 436, 449-454.
4. 2+ channel current. Am J Physiol 266, H2085-H2093.
5. Grainger J & Boachie-Ansah G (2001). Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134, 1003-1012.
6. Harris D, McCulloch AI, Kendall DA & Randall MD (2002). Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539, 893-902.
7. Hillard CJ (2000). Endocannabinoids and vascular function. J Pharmacol Exp Ther 294, 27-32.
8. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME & Kunos G (1996). Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118, 2023-2028.
9. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A & Kunos G (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96, 14136-14141.
10. Kapoor K, Arulmani U, Heiligers JP, Garrelds IM, Willems EW, Doods H, Villalon CM & Saxena PR (2003). Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs. Br J Pharmacol 140, 329-338.
11. Kass DA, Maughan WL, Guo ZM, Kono A, Sunagawa K & Sagawa K (1987). Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation 76, 1422-1436.
12. Kunos G, Batkai S, Offertaler L, Mo F, Liu J, Karcher J & Harvey-White J (2002). The quest for a vascular endothelial cannabinoids receptor. Chem Physics Lipids 121, 45-56.
13. Lake KD, Compton DR, Varga K, Martin BR & Kunos G (1997a). Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281, 1030-1037.
14. Lake KD, Martin BR, Kunos G & Varga K (1997b). Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29, 1204-1210.
15. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W & Parmentier M (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404.
16. Li J, Kaminski NE & Wang DH (2003). Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41, 757-762.
17. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A & Kunos G (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346, 835-840.
18. Malinowska B, Kwolek G & Gothert M (2001). Anandamide and methanandamide induce both vanilloid VR1- and cannabinoids CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364, 562-569.
19. Matsuda LA, Lolait SJ, Brownstein MJ, Young CA & Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
20. Mechoulam R, Fride E & Di Marzo V (1998). Endocannabionoids. Eur J Pharmacol 359, 1-18.
21. Mukhopadhyay S, Chapnick BM & Howlett AC (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol 282, H2046-H2054.
22. Munro S, Thomas KL & Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
23. Nakano K, Sugawara M, Ishihara K, Kanazawa S, Corin WJ, Denslow S, Biederman RW & Carabello BA (1990). Myocardial stiffness derived from end-systolic wall stress and logarithm of reciprocal of wall thickness. Contractility index independent of ventricular size. Circulation 82, 1352-1361.
24. Niederhoffer N & Szabo B (2000). Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 294, 707-713.
25. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT & Szabo C (2003). Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107, 896-904.
26. Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Hasko G & Szabo C (2002a). Activation of poly (ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300, 862-867.
27. Pacher P, Liaudet L, Mabley J, Komjati K & Szabo C (2002b). Pharmacologic inhibition of poly (adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 40, 1006-1016.
28. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E & Szabo C (2002c). The role of poly (ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51, 514-521.
29. Ralevic V, Kendall DA, Randall MD & Smart D (2002). Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: Roles in regulation of cardiovascular function. Life Sci 71, 2577-2594.
30. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P & Hogestatt ED (2000). Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol 130, 1483-1488.
31. Randall MD, Harris D, Kendall DA & Ralevic V (2002). Cardiovascular effects of cannabinoids. Pharmacol Ther 95, 191-202.
32. Ray AM, Benham CD, Roberts JC, Gill CH, Lanneau C, Gitterman DP, Harries M, Davis JB & Davies CH (2003). Capsazepine protects against neuronal injury caused by oxygen glucosae deprivation by inhibiting I(h). J Neurosci 23, 10146-10153.
33. Szolcsányi J (2000). Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? Trends Pharmacol Sci 21, 41-42.
34. Varga K, Lake KD, Huangfu D, Guyenet PG & Kunos G (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28, 682-686.
35. Varga K, Lake K, Martin BR & Kunos G (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278, 279-283.
36. Varga K, Wagner JA, Bridgen DT & Kunos G (1998). Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12, 1035-1044.
37. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G & Ertl G (2001a). Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38, 2048- 2054.
38. Wagner JA, Járai Z, Bátkai S & Kunos G (2001b). Haemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423, 203-210.
39. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR & Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
40. White R, Ho WS, Bottrill FE, Ford WR & Hiley CR (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 134, 921-929.
41. Zahner MR, Li DP, Chen SR & Pan HL (2003). Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 551, 515-523.
42. Zygmunt PM, Andersson DA & Högestätt ED (2002). Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22, 4720-4727.
43. Zygmunt PM, Petersson J, Andersson DA, Chuang H-H, Sorgard M, Di Marzo V, Julius D & Högestätt ED (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.